Actively Recruiting
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Led by International Agency for Research on Cancer · Updated on 2025-05-06
3000
Participants Needed
13
Research Sites
689 weeks
Total Duration
On this page
Sponsors
I
International Agency for Research on Cancer
Lead Sponsor
U
University of Chile
Collaborating Sponsor
AI-Summary
What this Trial Is About
Breast cancer has become a major public health problem in Latin America, as it is the most common form of cancer among women. Women are more likely to develop breast cancer at younger age, and to be diagnosed at an advanced stage compared to western women. Over the past twenty years, the mortality from breast cancer in Latin America has also been increasing very rapidly, and is currently the leading cause of cancer mortality. Little is known on specific risk factors for premenopausal breast cancer in general, and in Latin America in particular. There is a lack of specific knowledge on tumor molecular and pathological characteristics of breast cancer in Latin America premenopausal women, and this has major consequences on cancer treatment and survival. To improve our understanding on determinants of breast cancer incidence and mortality in young Latin America women and support preventive actions, we implemented an international, population-based multi-center study in Latin America: the PRECAMA study (Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a multicenter population-based case-control study). PRECAMA is coordinated by the International Agency for Research on Cancer (IARC), and is conducted within 4 Latin American countries: Mexico, Costa Rica, Colombia and Chile. Major aims of the project are the following: 1. To develop a multi-centric population-based case-control study on breast cancer in premenopausal women in several countries in Latin America with structured collection of individual, clinical, pathological information and biological specimens, according to strictly controlled protocols 2. To characterize, in these populations, the subtypes of premenopausal breast cancer on the basis of their molecular and pathological phenotypes 3. To improve the identification of specific endogenous/exogenous factors, and disentangle the interplay of these different factors with regard to breast tumor subtypes. 4. Provide advanced training, induce a structuring effect on the breast cancer research community in Latin America and influence the public health agenda regarding the management of breast cancer. The results of our study will be of utmost importance to understand the etiology of breast cancer in Latin America countries, and would provide important information on the role of modifiable exposures for breast cancer prevention.
CONDITIONS
Official Title
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Woman between 20 and 45 years old
- Woman less than 3 years older or younger than the case
- Living in the area where the study is taking place for at least the past 3 years
- Woman menstruated at least once in the past 12 months
- Woman diagnosed with primary breast cancer by histopathological examination (only for cases)
You will not qualify if you...
- Woman receiving tumor treatment such as radiotherapy, chemotherapy, or anti-estrogens (except treatment for non-melanoma skin cancers)
- Woman taking or has taken in the past 6 months medications like tamoxifen, raloxifene, toremifene, exemestane, letrozole, anastrozole, or megestrol
- Woman suffering from chronic kidney failure
- Woman having a condition that hinders adequate communication
- Woman who is pregnant or nursing
- Woman previously diagnosed with cancer (except non-melanoma skin cancers)
- Any other reason for exclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Barretos Cancer Hospital
Barretos, Brazil
Completed
2
INC
Santiago, Independencia, Chile
Active, Not Recruiting
3
Hso-Crsco
Santiago, Peñalolén, Chile
Active, Not Recruiting
4
FALP
Santiago, Providencia, Chile
Active, Not Recruiting
5
Grupo Infección y Cáncer. Universidad de Antioquia
Medellín, Antioquia, Colombia, 050010
Actively Recruiting
6
International Hospital of Colombia
Bucaramanga, Bucaramanga, Colombia
Actively Recruiting
7
Facultad de Medicina, Universidad del Norte
Barranquilla, Colombia
Completed
8
Hospital Internacional de Colombia Fundacion Cardiovascular de Colombia
Bucaramanga, Colombia
Actively Recruiting
9
SENOSAMA foundation
Bucaramanga, Colombia
Actively Recruiting
10
Instituto de Oncología HematoOncologos
Cali, Colombia
Completed
11
Public Health University of Narino
Pasto, Colombia
Actively Recruiting
12
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
San José, Provincia de San José, Costa Rica
Completed
13
Instituto Nacional de Salud Pública (INSP)
Cuernavaca, Morelos, Mexico, 69100
Completed
Research Team
S
Sabina Rinaldi, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here